MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

Search

Puma Biotechnology Inc

Fermé

SecteurSoins de santé

5.26 -0.19

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.1

Max

5.48

Chiffres clés

By Trading Economics

Revenu

2.9M

5.9M

Ventes

6.4M

52M

P/E

Moyenne du Secteur

5.343

36.442

Marge bénéficiaire

11.166

Employés

172

EBITDA

6.8M

11M

Recommandations

By TipRanks

Recommandations

Vente

Prévisions sur 12 Mois

-43.29% downside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

108M

266M

Ouverture précédente

5.45

Clôture précédente

5.26

Sentiment de l'Actualité

By Acuity

50%

50%

166 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Puma Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 oct. 2025, 22:33 UTC

Résultats

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 oct. 2025, 22:21 UTC

Principaux Mouvements du Marché

Dentsply Sirona Shares Rise After SEC Probe Ends

14 oct. 2025, 19:27 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 oct. 2025, 17:56 UTC

Principaux Mouvements du Marché

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 oct. 2025, 23:38 UTC

Market Talk

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 oct. 2025, 22:12 UTC

Market Talk
Résultats

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 oct. 2025, 21:40 UTC

Résultats

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 oct. 2025, 21:39 UTC

Résultats

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 oct. 2025, 21:38 UTC

Résultats

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 oct. 2025, 21:06 UTC

Résultats

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct. 2025, 20:50 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

14 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 oct. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

14 oct. 2025, 20:50 UTC

Market Talk
Résultats

Health Care Roundup: Market Talk

14 oct. 2025, 20:13 UTC

Résultats

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 oct. 2025, 20:01 UTC

Résultats

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 oct. 2025, 19:21 UTC

Market Talk
Résultats

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 oct. 2025, 19:12 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 oct. 2025, 19:08 UTC

Market Talk

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 oct. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 oct. 2025, 18:59 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 oct. 2025, 18:58 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 oct. 2025, 18:58 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 oct. 2025, 18:56 UTC

Acquisitions, Fusions, Rachats

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 oct. 2025, 18:46 UTC

Résultats

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct. 2025, 18:04 UTC

Résultats

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 oct. 2025, 18:01 UTC

Market Talk

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 oct. 2025, 17:54 UTC

Résultats

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 oct. 2025, 17:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 oct. 2025, 17:50 UTC

Market Talk

Lower Dollar Provides Some Strength in Grains -- Market Talk

Comparaison

Variation de prix

Puma Biotechnology Inc prévision

Objectif de Prix

By TipRanks

-43.29% baisse

Prévisions sur 12 Mois

Moyen 3 USD  -43.29%

Haut 4 USD

Bas 2 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Vente

2 ratings

0

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

3.07 / 3.075Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

166 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat